Insider buying last 90 days
No open-market insider purchases were filed for IQV in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every IQV insider filing, plotted on the chart in Gekko.Open IQV in Gekko
Gekko Brief
AI summaryNov 4 closeThis week's trading in IQVIA reflects a mix of analyst commentary following the stock's pullback from recent highs. Stifel Nicolaus maintained a Buy rating with a $303.00 price target, UBS reiterated a Buy with a $345.00 target, and RBC Capital kept a Buy rating with a $319.00 target, all weighing in on the healthcare technology name. Shares also fell 2.81% on one session amid a broader market decline, with the S&P 500 dropping 1.82% that day, before recovering somewhat into the close.
IQVIA closed at $263.79, up 0.5%, sitting between its 50-day average of $266.20 and its 200-day average of $209.88. The GekkoIndex reads 59.6, placing the stock in the Neutral zone, up 8.7 points over the past five readings. Price sits 2.4% above Gekko Fair Value of $257.52, keeping the gap within a tight range.
The next earnings report is scheduled for 4 February 2027, 91 days out, placing it outside a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. Seasonality data covering five years shows the next 20 trading days averaging a 4% return from this point in the calendar, with gains in 4 of those years. Analyst consensus across 15 firms stands at 13 buy and 2 hold ratings, with a consensus target of $311.89, representing 18.2% upside from current levels.
Written by AI from the Nov 4, 2026 close and checked automatically against the figures on this page.
IQVIA price vs fair value
Close $263.79200-day averageGekko Fair Value $257.52
IQVIA quick facts
- Market cap
- $43.47B
- P/E ratio
- 31.3
- Forward P/E
- 18.5
- EPS, TTM
- $8.22
- Revenue, TTM
- $17.31B
- Profit margin
- 8.1%
- Dividend yield
- —
- Beta
- 1.17
- Volume
- 1.38M avg 1.34M
- 1-year return
- +23.3%
- Typical daily move
- ±3.9%
- Typical 20-day move
- ±6.1%
- 50-day average
- $266.20
- 200-day average
- $209.88
- Next earnings
- Feb 4 before open
- Shares outstanding
- 164.8M
IQVIA swing-trade checklist
IQVIA scores 2 supportive, 3 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive3 mixed0 headwinds
- Trendmixed
Averages disagree
Close $263.79 sits between the 50-day ($266.20) and 200-day ($209.88) averages, or the averages disagree.
See the chart - GekkoIndexmixed
59.6, Neutral
Reading 59.6 is in the Neutral zone.
See the GekkoIndex - Fair valuemixed
2.4% above
Price is within 5% of Gekko Fair Value (2.4% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 91 days
Next report Feb 4, 2027, 91 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+4.0% on average
From this point in the calendar, the next 20 trading days averaged +4% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
IQVIA stock chart and price history
IQVIA closed at $263.79 on Nov 4, 2026, +23.3% over the past year, inside a 52-week range of $154.50 to $284.50.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +1.5%
- 3 months
- +13.5%
- 6 months
- +49.5%
- 1 year
- +23.3%
The full IQV chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open IQV in Gekko
Follow IQVIA through every session
Put IQV on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track IQV in GekkoFree for 7 days. No credit card required.
About IQVIA
IQVIA helps companies in the life sciences space make sense of health-related information, offering software, data services, and clinical trial support to guide decisions about treatments and patient care. It serves pharmaceutical, biotech, medical device, diagnostic, and consumer health businesses in regions spanning the Americas, Europe, Africa, and Asia-Pacific, and is recognized for combining data analytics with hands-on research services.
The company operates through three main areas. One focuses on cloud-based software, real-world data, and consulting, including granular tracking of drug sales and prescribing habits across pharmacies, hospitals, and mail-order outlets. Another handles the planning and execution of clinical trials, along with a set of laboratory testing services covering areas like genomics, bioanalysis, and vaccine research. The third connects clients with healthcare providers and patients while offering support in medical strategy and affairs. IQVIA also works alongside HealthCore, Inc. as part of its operations.
The company traces its start to 1982 and operates out of Durham, North Carolina. Before adopting its current identity in November 2017, it was known as Quintiles IMS Holdings, Inc. Shares of IQVIA are listed on the NYSE under the ticker IQV.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- iqvia.com
IQVIA GekkoIndex: the smart money zone
IQVIA’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 59.6, in the Neutral zone, up 8.7 points over five sessions.
59.6Neutral
Up 8.7 points over five sessions.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 43 | −1.3% | −1.5% | ||
| Accumulation | 231 | +0.2% | −0.7% | ||
| Neutral (current zone) | 377 | +0.7% | +2.9% | ||
| Distribution | 40 | −0.9% | −0.8% | ||
| Selling | 6 | Too few readings yet | |||
Average IQV share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.0% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the IQV price, zone by zone.Track IQV in Gekko
Is IQVIA stock overvalued? Gekko Fair Value
IQVIA trades 2.4% above Gekko Fair Value of $257.52, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what IQVIA shares are worth, recalculated every trading day.
$257.52
Gekko Fair Value, Nov 4, 2026
2.4% above fair value · About fair value
At the end of Aug 2026 the price was 6.3% above the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open IQV in Gekko
IQVIA insider and Congress trading
No open-market insider purchases were filed for IQVIA, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in IQV were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for IQV, plotted on the chart in Gekko.Open IQV in Gekko
Buybacks
IQVIA has been buying back its own shares.
- Latest authorization
- $2.00B, May 7, 2026
- Bought back, quarter ended Jun 30, 2026
- $398.0M
- As a share of market cap
- 0.92%
- Trailing four quarters
- $2.19B
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds IQV.
1added0opened0trimmed3sold out
Which funds are on each side, name by name.Unlock in Gekko
IQVIA earnings: next date and track record
IQVIA reports on Feb 4, 2027, before the open (91 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Feb 4, 2027
Expected before the open, 91 days away
- EPS estimate
- $3.60
- Revenue estimate
- $4.53B
6 of 8reports beat the EPS estimate
±7.6%average move across the report
6 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 28, 2026 AI summary
- What they said
- IQVIA's Q2 2026 earnings call highlighted strong financial performance, with revenue, adjusted EBITDA, and adjusted diluted EPS all exceeding the high end of guidance. Organic growth accelerated to 6% year-over-year, and adjusted EBITDA grew 9.2% y/y. R&D Solutions showed robust bookings ($3.15B net new bookings, 1.22 book-to-bill) with broad-based strength across FSO, FSP, and EBP. Management emphasized improving market conditions, operational productivity gains (including some benefits from AI), and a favorable outlook driven by rising RFP flows and client demand tied to AI-driven drug discovery. Adjusted diluted EPS of $3.15 (+12.1% y/y) and GAAP EPS of $1.53 were reported. Management noted cancellations and pass-throughs were within normal ranges, acquisitions contributed ~250 bps to growth, and Charles River assets added ~$75-80M revenue for the year. Backlog quality review indicated only ~5% possibly inactive trials versus competitor claims of ~15%; backlog next-12-month revenue is at record $9.1B (~7.5% growth). Management reiterated contracted bookings policy. Guidance was maintained with improved revenue expectations (organic revenue +100bps) and flat full-year margins driven by offsetting items (FX, pass-throughs, M&A, productivity).
- Guidance
- Company raised revenue guidance with a 100 bps improvement in organic revenue growth (management cited stronger market demand and better execution). They maintained full-year adjusted EBITDA margin guidance (flat) due to offsetting items: operational productivity gains vs. pass-throughs, FX and acquisitions (Charles River lower margins). Acquisitions are expected to add ~$75-80M to 2026 revenue; acquisition contribution ~2.5% in quarter. Backlog/next-12-month revenue at record ~$9.1B. No specific numeric FY revenue or EPS guidance printed in transcript segments provided beyond the described increases and margin guidance.
- Risks flagged
- Risks mentioned include FX volatility (historical headwind but changing), pass-through revenue growth (zero-margin impact and a drag on adjusted EBITDA margin), potential cancellations (noted as within historical range), regulatory/privacy frameworks for AI/data use, and the long-cycle nature of R&D impacting timing of revenue realization. Also M&A integration (Charles River lower margin) can weigh on margins. Management noted forward-looking statement caveats and SEC filing disclosures.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 28, 2026 | $2.53 est $2.72 | $4.37B est $4.30B | +16.1% |
| May 5, 2026 | $2.90 est $2.82 | $4.15B est $4.10B | +9.6% |
| Feb 5, 2026 | $3.42 est $3.40 | $4.36B est $4.24B | −7.4% |
| Oct 28, 2025 | $3.00 est $2.98 | $4.10B est $4.08B | +0.2% |
| Jul 22, 2025 | $2.81 est $2.77 | $4.02B est $3.97B | +22.2% |
| May 6, 2025 | $2.70 est $2.63 | $3.83B est $3.77B | +0.7% |
| Feb 6, 2025 | $2.42 est $2.09 | $3.96B est $3.93B | +1.3% |
| Oct 31, 2024 | $1.55 est $1.92 | $3.90B est $3.87B | −3.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
IQVIA stock forecast and analyst price targets
Analysts’ average 12-month price target for IQVIA is $311.89, +18.2% from the last close, from 15 firms rating the stock in the last 90 days.
$311.89consensus 12-month target, +18.2% from the last close
Now $263.79Avg $311.89
Low $270High $346
Each firm’s latest rating in the last 90 days: 15 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 29 | TD Cowen | $307 | +16.4% |
| Oct 29 | Leerink Partners | $320 | +21.3% |
| Oct 28 | J.P. Morgan | $325 | +23.2% |
| Oct 28 | Evercore ISI | $310 | +17.5% |
| Oct 28 | UBS | $345 | +30.8% |
+2.9%average 20-day move after past Neutral readings
+4.0%average move over the next 20 trading days in the last 5 years
±3.9%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
IQVIA seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, IQVIA averaged +4.0% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +3.3% | 3 of 5 |
| Next 10 trading days | +1.5% | 4 of 5 |
| Next 15 trading days | +4.4% | 4 of 5 |
| Next 20 trading days | +4.0% | 4 of 5 |
| Next 30 trading days | +3.3% | 3 of 5 |
For scale, IQV’s typical 20-trading-day move in either direction is about 6.1%.
IQVIA market cap and key statistics
IQVIA’s market cap is $43.47B, with a P/E ratio of 31.3 and revenue of $17.31B over the last twelve months.
Valuation
- Market cap
- $43.47B
- P/E ratio
- 31.3
- Forward P/E
- 18.5
- EPS, TTM
- $8.22
- Gekko Fair Value
- $257.52
Trading
- Volume
- 1.38M
- Avg volume, 20 days
- 1.34M
- 52-week high
- $284.50
- 52-week low
- $154.50
- Shares outstanding
- 164.8M
Financials
- Revenue, TTM
- $17.31B
- Profit margin
- 8.1%
- Return on equity
- 21.4%
- Quarterly earnings growth, YoY
- +8.8%
Risk and income
- Beta
- 1.17
- Typical daily move
- ±3.9%
- Typical 20-day move
- ±6.1%
IQVIA stock news this week
Coverage of IQVIA this week reads neutral: 5 positive, 6 neutral and 2 negative headlines.
- IQVIA Holdings Inc. (IQV.MX) Seasonal returns chartYahoo Finance UK, Nov 3
- IQVIA Holdings Inc. (IQV.MX) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada, Nov 3
- IQVIA Holdings Inc. (IQV) stock price, news, quote and historyYahoo Finance Australia, Oct 31
- IQVIA Holdings Inc. (IQV) Seasonal returns chartYahoo Finance UK, Oct 31
- IQVIA Holdings Inc. stock underperforms Friday when compared to competitorsMarketWatch, Oct 30
- Analysts’ Top Healthcare Picks: Perrigo Company (PRGO), IQVIA Holdings (IQV)The Globe and Mail, Oct 30
IQVIA peers
IQVIA’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Distribution | 18.1% below |
| GILDGilead Sciences | Distribution | 12.0% above |
| MRNAModerna | Neutral | 54.9% above |
| NTRANatera | Neutral | 0.8% below |
| UTHRUnited Therapeutics | Distribution | 9.1% below |
| NBIXNeurocrine Biosciences | Distribution | 31.9% below |
A peer links to its own page where one exists.
IQVIA stock FAQ
What is IQVIA’s market cap?
IQVIA’s market cap is $43.47B at the Nov 4, 2026 close of $263.79, with 164.8M shares outstanding. The shares trade on a P/E ratio of 31.3.
What is the IQVIA stock forecast?
The consensus analyst 12-month price target for IQVIA is $311.89, +18.2% from the last close. Of the 15 firms that rated the stock in the last 90 days, 13 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is IQVIA stock overvalued or undervalued?
On Gekko’s estimate IQVIA is about fair value: the Nov 4, 2026 close of $263.79 is 2.4% above Gekko Fair Value of $257.52. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does IQVIA report earnings next?
IQVIA is expected to report on Feb 4, 2027, before the market opens (91 days away). Analysts expect earnings of $3.60 per share on revenue of $4.53B. IQVIA beat the earnings estimate in 6 of its last 8 reports, moving 7.6% on average across the report.
What is IQVIA’s 52-week high and low?
IQVIA’s 52-week high is $284.50 and its 52-week low is $154.50; it closed at $263.79 on Nov 4, 2026, +23.3% over the past year. Over the last five years the shares peaked at $285.61 on Dec 30, 2021.
Is IQVIA stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (earnings risk and seasonality), 3 as mixed (trend, gekkoindex and fair value). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See IQVIA the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.